FDA AI Rollout Gets Cautiously Optimistic Reception

By Jessica Karins / June 3, 2025 at 5:05 PM

Stakeholders are striking a measured tone on FDA’s announcement that it will swiftly role out the use of artificial intelligence-assisted reviews across the whole agency, saying there are reasons for concern but it’s necessary to take innovative steps to speed up medical product reviews.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.